{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tocilizumab+or+sarilumab", "query": { "intervention": "tocilizumab or sarilumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T04:21:08.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" }, { "nct_id": "NCT06418529", "title": "A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tofacitinib", "type": "DRUG" }, { "name": "tumor necrosis factor inhibitors (TNFi)", "type": "DRUG" }, { "name": "abatacept", "type": "DRUG" }, { "name": "tocilizumab or sarilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21340, "start_date": "2024-05-15", "completion_date": "2024-07-19", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06418529" }, { "nct_id": "NCT05638932", "title": "Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aetion, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1442, "start_date": "2020-06-16", "completion_date": "2023-09-25", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05638932" }, { "nct_id": "NCT04692493", "title": "RA-PRO PRAGMATIC TRIAL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "targeted synthetic DMARD class", "type": "DRUG" }, { "name": "non-TNFi-biologic class", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 924, "start_date": "2021-09-22", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 48, "location_summary": "Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more", "locations": [ { "city": "Auburn", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692493" }, { "nct_id": "NCT03564340", "title": "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Ovarian Cancer", "Recurrent Fallopian Tube Cancer", "Recurrent Primary Peritoneal Cancer", "Recurrent Endometrial Cancer", "Endometrial Cancer", "Low-grade Serous Ovarian Cancer" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 890, "start_date": "2018-05-21", "completion_date": "2027-05-10", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564340" }, { "nct_id": "NCT04278404", "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronavirus Infection (COVID-19)", "Pulmonary Arterial Hypertension", "Urinary Tract Infections in Children", "Hypertension", "Pain", "Hyperphosphatemia", "Primary Hyperaldosteronism", "Edema", "Hypokalemia", "Heart Failure", "Hemophilia", "Menorrhagia", "Insomnia", "Pneumonia", "Skin Infection", "Arrythmia", "Asthma in Children", "Bronchopulmonary Dysplasia", "Adrenal Insufficiency", "Fibrinolysis; Hemorrhage", "Attention Deficit Hyperactivity Disorder", "Multisystem Inflammatory Syndrome in Children (MIS-C)", "Kawasaki Disease", "Coagulation Disorder", "Down Syndrome" ], "interventions": [ { "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 5000, "start_date": "2020-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278404" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-10-04T04:21:08.578Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" } ] }